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Biotechnologies that aim to prevent smoking and tobacco-related disease may emerge as 
unintended by-products of research on 
the genetics of nicotine dependence 
and the effectiveness 
of nicotine vaccines for 
smoking cessation. For 
many advocates of tobacco 
control, any discussion of 
the genetics of smoking 
is anathema because of 
the tobacco industry’s use 
of Fisher’s [1] genetic 
hypothesis to argue that 
cigarette smoking did not 
cause lung cancer [2,3]. 
Advocates of tobacco 
control say that the goal of 
tobacco policy should be to 
eliminate cigarette smoking 
by imposing high taxes on 
tobacco products, preventing 
the tobacco industry from 
promoting its products, 
restricting access to tobacco 
and opportunities to smoke, 
and minimising nonsmokers’ exposure 
to environmental tobacco smoke 
[4]. These policies have substantially 
reduced smoking prevalence in the 
developed countries that have adopted 
them [4].
Even if one agrees with these 
policies, as I do, it would be unwise to 
ignore evidence that genetic factors 
play a role in smoking initiation 
and persistence or neurobiological 
explanations of why some smokers 
fi nd it so diffi cult to quit. Indeed, 
the past misuse of genetic research 
on nicotine and the possible public 
misunderstanding of the role of 
nicotine vaccines make it all the 
more important for public health 
practitioners and genetic and 
neurobiological researchers to be 
well acquainted with some of the 
superfi cially attractive but mistaken 
ways in which this work may be used. 
In this short paper, I briefl y explain 
why it would be unwise to use genetic 
and neurobiological knowledge to 
prevent cigarette smoking and tobacco-
related disease. However implausible 
these uses may seem to those who are 
well informed about the genetics of 
tobacco use or tobacco-control policy, 
it is the preventive uses of genetic 
information and nicotine vaccines that 
most excite the interest of the media 
and the public. The major challenges 
that these approaches face need to 
be widely understood if we are to 
prevent these superfi cially attractive but 
controversial uses from undermining 
effective control policies and the 
development of better methods of 
helping smokers to quit.
The Genetics of Smoking 
Twin studies of cigarette smoking 
[5,6] estimate that the heritability of 
smoking initiation is 50% and that for 
smoking persistence is 70% [5,7,8]. 
There are a number of plausible 
“candidate genes” that predict an 
increased risk of nicotine dependence 
[5,8]. These include 
polymorphisms that affect 
nicotine metabolism, as well 
as dopamine receptors and 
transporters that mediate 
reward in the nucleus 
accumbens [9]. The most 
plausible hypothesis is that 
multiple genes are involved 
in smoking initiation and 
persistence [5,7,10,11], 
each of which only modestly 
increases the risk of 
developing dependence. 
The relative risks for the 
alleles that have been most 
consistently associated 
with smoking initiation, 
adoption, persistence, and 
cessation are typically less 
than 1.30 [5], well within 
the range of associations 
observed between polymorphisms and 
other human diseases, namely, 1.2–1.5 
[12]. 
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Figure 1. Gross Pathology of the Lung Showing Centrilobular 
Emphysema Characteristic of Smoking 
(Photo: Edwin P. Ewing, Jr./Centers for Disease Control and Prevention)
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Predictive Testing for Genetic Risks 
of Nicotine Dependence 
The predictive testing of genetic risk 
dependence is one of the fi rst uses that 
journalists often suggest for research on 
the genetics of nicotine dependence. 
In this scenario, the population would 
be screened for susceptibility alleles 
with the aim of giving preventive 
behavioural and pharmacological 
interventions to individuals who are at 
higher genetic risk of smoking [13]. 
There is an obvious objection to this 
proposal: that it is not good public 
health policy to encourage people 
to smoke tobacco, regardless of their 
genetic risk of dependence [7]. 
An alternative rationale is that 
screening would allow individuals who 
were at highest genetic risk of nicotine 
dependence to make an informed 
decision to avoid tobacco smoking. Even 
if we value individual autonomy highly, 
genetic screening for nicotine 
dependence is unlikely to be a 
good policy for the following 
reasons [14]. 
First, when multiple genes 
predispose to a condition, 
individual susceptibility 
alleles only predict a very 
modestly increased risk of 
dependence [15]. Testing 
multiple alleles would 
improve prediction if the 
results of the multiple tests 
were combined [16,17], but 
the larger the number of 
genes that are involved in 
disease susceptibility, the 
less useful most individuals 
will fi nd information about 
their genotype. This is 
because as the number of 
alleles increases, the risk 
distribution tends to the log 
normal [17], a distribution 
in which the number of 
persons with very high risk 
combinations of multiple 
genes is very small and in 
which the majority will be at 
average genetic risk [7,16].
Second, the above means 
that a very large number of 
individuals would need to 
be screened to identify the 
few at highest risk [18,19]. 
For example, Yang et al. 
[20] simulated screening 
for 5 susceptibility alleles, 
each with a relative risk 
(RR) ranging from 1.5 to 3.5 and a 
prevalence in the population between 
0.10 and 0.25 (all within the range 
of empirical data). One of these 
alleles was assumed to interact with 
an environmental exposure with 
a prevalence of 15% and a RR of 
2.0. Their simulation showed that 
those who screened positively on 
all fi ve genes had an 81% chance of 
developing the disease; this rose to 89% 
if they had also been exposed to the 
environmental risk factor. However, 
these risks applied to only four persons 
in 100,000, and only 79 in 100,000 
would have a greater than 50% risk. 
Third, predictive genetic testing 
may have unintended adverse effects. 
This would be the case, for example, if 
testing adolescents for susceptibility to 
nicotine dependence increased their 
preparedness to initiate smoking—as 
could happen, for example, if they 
were prompted to test the accuracy of 
the genetic predictions by smoking [7]. 
Fourth, screening is only ethically 
justifi able if there is an effective 
intervention to prevent the disorder 
in those who are identifi ed as being 
at increased genetic risk [15,21]. 
“Avoid smoking” is good health 
advice, regardless of one’s genetic 
susceptibility. The prospect of 
combining genetic screening with 
some preventive intervention sounds 
a more appealing option, especially 
when such an intervention—a vaccine 
against nicotine—is being developed 
and trialled by three pharmaceutical 
companies for smoking cessation [22]. 
Preventive Use of a Nicotine 
Vaccine
A “nicotine vaccine” induces the 
immune system to produce antibodies 
that bind to nicotine and prevent it 
from crossing the blood–
brain barrier to act on 
receptors in the brain [23-
25]. Animal studies have 
shown that attaching nicotine 
to a suitable antigenic protein 
(e.g., [23,24]) produces 
antibodies that have a high 
affi nity for nicotine [23,25]. 
Vaccination of animals 
attenuates nicotine effects 
[24], abolishes nicotine self-
administration [23], and 
suppresses dopamine release 
in the nucleus accumbens 
[26]. 
Active vaccination against 
nicotine could reduce relapse 
to smoking in abstinent 
smokers by attenuating the 
pharmacological effects of 
nicotine during the fi rst few 
months after quitting, when 
most smokers relapse [25]. 
A nicotine vaccine could be 
circumvented by increasing 
the dose of nicotine, but 
attenuating the rewarding 
effects of nicotine may 
nonetheless be enough 
to reduce relapse rates in 
smokers by making a lapse 
less likely to lead to a return 
to daily smoking [22,25]. This 
promising immunological 
technology for improving the 
success of smoking cessation 
is currently in trials [22,25].
DOI: 10.1371/journal.pmed.0020266.g001
Vaccination against nicotine could reduce relapse to smoking in 
abstinent smokers 
(Photo: Bill Branson/National Cancer Institute) 
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The term “vaccine” inevitably prompts 
journalists to ask about its possible 
preventive use. Misconceptions that a 
vaccine will produce lifelong immunity 
against nicotine may prompt parents to 
vaccinate their children [27]. As minors, 
children would not be legally able to 
consent to vaccination, but since parents 
already make choices for their children 
about other vaccines and interventions 
that affect their lives (e.g., their diet 
and education), some have argued 
that vaccination against nicotine and 
other drugs is simply another decision 
that parents should be able to make 
on behalf of their children [27]. This 
argument is likely to be contested by 
civil libertarians and by adolescents 
who disagree with their parents’ wishes. 
One can expect the tobacco industry to 
amplify such dissenting views.
Even if we set aside the ethical issues, 
there are major practical obstacles to 
the preventive use of a nicotine vaccine 
in children. First, the limited period of 
protection provided by existing vaccines 
would require booster injections, 
perhaps every two or three months 
throughout adolescence [28]. Second, 
the fact that the vaccine could be 
circumvented by using higher doses of 
nicotine means that vaccination could 
be counterproductive if adolescents 
were prompted to test its effi cacy. Third, 
it would be costly to universally vaccinate 
children against nicotine with a vaccine 
that would probably have only modest 
preventive effi cacy. These obstacles (and 
the high regulatory hurdles that such 
a vaccine might be expected to have to 
leap when used preventively in children) 
make it unlikely that universal nicotine 
vaccination would be publicly funded.
“Indicated vaccination” of “high risk” 
adolescents seems a more plausible 
option because it would be much less 
expensive to only vaccinate young 
people who are at “high genetic risk” 
of smoking. The feasibility of this 
approach is also doubtful, given the 
likely low predictive validity of genetic 
screening for smoking risk (outlined 
above), the doubtful preventive effi cacy 
of a nicotine vaccine, and the possible 
adverse effects of vaccination, such 
as stigmatisation of those who screen 
positive, and discrimination against 
them by third parties, such as life or 
health insurance companies. 
The “off-label” use of a nicotine 
vaccine by a physician acting at the 
request of a parent is the most likely 
way in which a vaccine will be used 
preventively. It is diffi cult to see how 
this can be prevented if a nicotine 
vaccine is approved for therapeutic use, 
other than by education of physicians 
and parents about the limitations of 
this approach. 
Screening for Genetic 
Susceptibility to Tobacco-Related 
Diseases
Genetic factors also appear to play 
a role in susceptibility to many 
nonfamilial types of cancer, although 
there is disagreement about how large 
a role this is [29–32]. There is evidence 
that polymorphisms that affect the 
metabolism of carcinogens in tobacco 
smoke and repair of damage to DNA 
may increase the risk of smokers 
developing lung cancer [33–35]. There 
are also indications that polymorphisms 
may affect the likelihood of smokers 
developing heart disease [36] and 
chronic obstructive lung disease 
(Figure 1) [37].
Many ambivalent smokers may be 
attracted by the superfi cially plausible 
idea that they could continue to smoke 
with impunity if they did not have any 
of the alleles that predict an increased 
risk of smoking-related diseases [38]. 
However, this type of screening is 
very unlikely to work, for reasons that 
need to be widely understood by the 
community. 
First, if, as seems most likely, multiple 
genes are involved in susceptibility to 
multiple tobacco-related diseases, then 
the ability to predict tobacco-related 
disease risk from genetic tests may not 
improve on the prediction of disease 
risk from smoking status. 
Second, cigarette smoking causes 
multiple diseases, with lung and other 
cancers, heart disease and chronic 
obstructive lung disease being the most 
prevalent. This means that predicting 
one’s genetic risk of only the most 
common tobacco-related diseases 
would involve testing a large number of 
polymorphisms. 
Third, because multiple susceptibility 
alleles would have to be tested for 
multiple diseases, most smokers 
would be at increased genetic risk 
of developing at least one smoking-
related disease [38]. For example, if we 
screened for six different susceptibility 
alleles (each with a RR of 1.5, a 
prevalence of 10%, and multiplicative 
risks) for each of fi ve major tobacco-
related diseases (lung cancer, coronary 
heart disease, chronic lung disease, 
other cancers, and stroke), then only 
3% of the screened population would 
not be at increased risk of developing 
any of the diseases. Conversely, 97% of 
smokers would be at increased risk of 
developing at least one of these diseases 
if they continued to smoke.
Conclusion
The preventive use of genetic and 
vaccine biotechnologies—screening the 
population for genetic susceptibility 
to nicotine dependence, vaccinating 
children who do not smoke against 
the effects of nicotine, and screening 
smokers for polymorphisms that 
predict increased susceptibility 
to tobacco-related diseases—are 
superfi cially attractive tobacco policy 
options that are of doubtful effi cacy, 
cost-effectiveness, and ethicality. We 
must ensure that the speculative use of 
these technologies does not undermine 
effective tobacco-control policies and 
the development of more effective ways 
of helping cigarette smokers to quit. 
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